The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

详细信息    查看全文

• 作者：Martinetti ; Antonia ; Ferrari ; Leonardo ; Celio ; Luigi ; Mariani ; Luigi ; Miceli ; Rosalba ; Zilembo ; Nicoletta ; et. al.
• 关键词：Breast cancer ; Bone metabolism markers ; Growth factors ; Cytokines ; Oestrogens ; Gonadotrophin releasing-hormone ; Aromatase inhibitors
• 刊名：The Journal of Steroid Biochemistry and Molecular Biology
• 出版年：2000
• 出版时间：December 1, 2000
• 年：2000
• 卷：75
• 期：1
• 页码：65-73
• 全文大小：112 K

文摘

Background: the combination of a luteinising hormone–releasing hormone (LH–RH) analogue and an aromatase inhibitor (AI) induces greater oestrogen suppression than the analogue alone in premenopausal breast cancer. However, very few data on the biological effects of such a combination are currently available. Aim of the study: the short-term effects of treatment with the LH–RH analogue triptorelin alone or in association with the AI formestane on bone metabolism were investigated in premenopausal breast cancer. Circulating levels of the bone formation markers carboxy-terminal and amino-terminal propeptides of type I procollagen (PICP and PINP) and the bone resorption marker cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) were assessed. In addition, serum levels of insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3 and interleukin 6 (IL-6) were evaluated. Patients and methods: twenty-one patients with advanced breast cancer were randomly given triptorelin monthly alone (n